Stock Events

Stock Events

SymBio Pharmaceuticals Limited 

$0.5579
16
+$0.00+0% Thursday 20:00

Statistics

Day High
0.6603
Day Low
0.6603
52W High
1.1944
52W Low
0.5579
Volume
1
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.23
-0.2
-0.17
-0.14
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYMQY. It's not an investment recommendation.
Apple
3
AAPL
Coca-Cola
3
KO
Mitsubishi UFJ Financial Group
3
8306.TSE
NTT
3
9432.TSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca operates in similar therapeutic areas, including oncology, which is a key focus for SymBio.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb competes directly in the oncology and hematology space, areas of focus for SymBio.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad portfolio that includes oncology drugs, competing with SymBio's cancer-focused pipeline.
Merck
MRK
Mkt Cap305.12B
Merck is a leading company in oncology, directly competing with SymBio's cancer treatment developments.
Novartis
NVS
Mkt Cap293.94B
Novartis has a strong presence in oncology and hematology, competing with SymBio's product offerings.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences focuses on areas like oncology and hematology, overlapping with SymBio's interests.
Rogers
ROG
Mkt Cap2.52B
Roche, through its Genentech division, is a major player in oncology, posing competition to SymBio.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's focus on innovative treatments in oncology and hematology makes it a competitor to SymBio.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment, competes in the oncology market, relevant to SymBio's focus.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has a growing oncology portfolio, which puts it in direct competition with SymBio's therapeutic areas.

About

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded by Fuminori Yoshida on March 25, 2005 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Fuminori Yoshida
Employees
91
Country
United States
ISIN
US87150Y1001

Listings

TSE
JP
4582.TSE
OTC Link
US
SYMQY

0 Comments

Share your thoughts

FAQ

What is SymBio Pharmaceuticals Limited stock price today?▼
The current price of SYMQY is $0.56 USD — it has increased by +0% in the past 24 hours. Watch SymBio Pharmaceuticals Limited stock price performance more closely on the chart.
What is SymBio Pharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange SymBio Pharmaceuticals Limited stocks are traded under the ticker SYMQY.
When is the next SymBio Pharmaceuticals Limited earnings date?▼
SymBio Pharmaceuticals Limited is going to release the next earnings report on July 30, 2026.
What were SymBio Pharmaceuticals Limited earnings last quarter?▼
SYMQY earnings for the last quarter are -0.23 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does SymBio Pharmaceuticals Limited have?▼
As of July 14, 2026, the company has 91 employees.
In which sector is SymBio Pharmaceuticals Limited located?▼
SymBio Pharmaceuticals Limited operates in the Health & Wellness sector.
When did SymBio Pharmaceuticals Limited complete a stock split?▼
The last stock split for SymBio Pharmaceuticals Limited was on June 26, 2019 with a ratio of 1:4.
Where is SymBio Pharmaceuticals Limited headquartered?▼
SymBio Pharmaceuticals Limited is headquartered in Minato, United States.